Review
Biochemistry & Molecular Biology
Carlos Jimenez-Cortegana, Alba Garcia-Galey, Malika Tami, Pilar del Pino, Isabel Carmona, Soledad Lopez, Gonzalo Alba, Victor Sanchez-Margalet
Summary: NAFLD affects a quarter of the global population and poses a significant health and economic burden across all countries. The lack of approved pharmacotherapy and well-established diagnostic strategies for this disease highlights the urgency for further research and management efforts. Studies have shown a strong relationship between the hormone leptin and the development of NAFLD, suggesting potential advancements in disease management through further investigation of its role.
Review
Endocrinology & Metabolism
Chen Liang, Zhiyuan Yu, Li Bai, Wei Hou, Shan Tang, Wei Zhang, Xinyue Chen, Zhongjie Hu, Zhongping Duan, Sujun Zheng
Summary: This study evaluated the association between serum bilirubin levels and metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD). The results showed an inverse correlation between serum total bilirubin (TBIL) and direct bilirubin (DBIL) levels with MetS in healthy population. Serum indirect bilirubin (IBIL) levels were inversely associated with the onset and degree of non-alcoholic steatohepatitis (NASH) in NAFLD patients. Exogenous bilirubin supplement may be a potential strategy to lower the risk of developing MetS and NAFLD.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Cell Biology
Daryl Ramai, Antonio Facciorusso, Erika Vigandt, Bryan Schaf, Waleed Saadedeen, Aditya Chauhan, Sara di Nunzio, Aashni Shah, Luca Giacomelli, Rodolfo Sacco
Summary: NASH is a chronic and progressive form of non-alcoholic fatty liver disease with increasing global incidence, posing an epidemic and public health threat. The disease is associated with major morbidity and mortality, with patients at risk of developing hepatocellular carcinoma. Current evidence suggests a multi-hit model involving various pathways leading to progressive fibrosis and oncogenesis, highlighting the complexity of the disease.
Review
Gastroenterology & Hepatology
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, with a prevalence of approximately 30%. Its prevalence varies depending on comorbidities and is expected to increase due to the rising obesity rates. NAFLD is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). This article provides a brief overview of NAFLD's definition and classification based on current knowledge.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Medicine, General & Internal
Rafael Paternostro, Michael Trauner
Summary: Non-alcoholic fatty liver disease (NAFLD) is a liver disease with various pathologies. In addition to lifestyle changes and a few specific medications, there are new treatment options being studied. Treating complications of end-stage liver disease caused by non-alcoholic steatohepatitis (NASH) is important for the treatment of the complete clinical spectrum of NAFLD.
JOURNAL OF INTERNAL MEDICINE
(2022)
Review
Environmental Sciences
Alexey A. Tinkov, Michael Aschner, Abel Santamaria, Alfred R. Bogdanov, Yousef Tizabi, Miriam B. Virgolini, Ji-Chang Zhou, Anatoly V. Skalny
Summary: The objective of this study was to review existing epidemiological and laboratory findings supporting the role of toxic metal exposure in non-alcoholic fatty liver disease (NAFLD). The existing studies demonstrate a link between exposure to cadmium, lead, arsenic, and mercury and an increased risk of NAFLD, as well as altered liver injury markers. Laboratory studies also show that metal exposure leads to hepatic lipid accumulation and affects metabolic pathways and inflammatory response.
ENVIRONMENTAL RESEARCH
(2023)
Review
Health Care Sciences & Services
Laura Valenzuela-Vallejo, Despina Sanoudou, Christos S. Mantzoros
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with various complications. The lack of non-invasive diagnosis and effective treatment calls for a more specific subcategorization of fatty liver disease (FLD). A precision medicine approach based on subcategorization is expected to improve patient care and reduce healthcare costs associated with FLD.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Chenhui Ma, Li Han, Zheying Zhu, Cheng Heng Pang, Guoyu Pan
Summary: This review provides an overview of mineral metabolism and its relationship with the pathogenesis of NAFLD. Perturbation of minerals has been found to be associated with the pathological features of NAFLD and potential therapeutic strategies are highlighted. Future directions for targeting mineral metabolism in the treatment of NAFLD are also discussed.
BIOCHEMICAL PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
David Hojland Ipsen, Pernille Tveden-Nyborg
Summary: NAFLD is a leading chronic liver disease globally, with a complex pathogenesis involving crosstalk between multiple cellular networks. Extracellular vesicles (EVs) have gained attention as mediators of cellular communication, potentially serving as disease markers and treatment targets in future NAFLD research.
Review
Endocrinology & Metabolism
Li Rong, Junyan Zou, Wei Ran, Xiaohong Qi, Yaokai Chen, Hongjuan Cui, Jinjun Guo
Summary: Non-alcoholic fatty liver disease (NAFLD), now renamed as metabolic (dysfunction) associated with fatty liver disease (MAFLD), is a series of diseases characterized by excessive lipid deposition in the liver and often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. While changes in diet and lifestyle are recognized as non-drug treatment strategies, current drug therapies mainly target the pathogenic factors, key links of pathogenesis, and related metabolic disorders of NAFLD. There is still a lack of specific drugs, but treatments based on the enterohepatic axis, targeting gut microbiota, and new metabolism-regulating drugs are emerging.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Gastroenterology & Hepatology
Sakura Yamamura, Dan Nakano, Ryuki Hashida, Tsubasa Tsutsumi, Takumi Kawaguchi, Michiaki Okada, Hiroshi Isoda, Hirokazu Takahashi, Hiroo Matsuse, Yuichiro Eguchi, Yoshio Sumida, Atsushi Nakajima, Lynn Gerber, Zobair M. Younossi, Takuji Torimura
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide and it is important to assess all associated outcomes including patient-reported outcomes (PROs). The Chronic Liver Disease Questionnaire (CLDQ)-NAFLD/NASH is a specific instrument developed for this purpose and has shown excellent reliability and validity in international clinical trials.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Medicine, General & Internal
Guanlin Li, Xinrong Zhang, Huapeng Lin, Lilian Yan Liang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong
Summary: New developments in non-invasive assessment methods show potential in diagnosing and monitoring NAFLD. Magnetic resonance imaging and blood biomarkers can be used to detect hepatic steatosis and fibrosis, but further research is needed to confirm their role in treatment monitoring.
CHINESE MEDICAL JOURNAL
(2022)
Article
Immunology
Yamei Duan, Xiongfeng Pan, Jiayou Luo, Xiang Xiao, Jingya Li, Prince L. Bestman, Miyang Luo
Summary: This study found a significant association between inflammatory cytokines and non-alcoholic fatty liver disease (NAFLD). Increased concentrations of C-reactive protein (CRP), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and intercellular adhesion molecule-1 (ICAM-1) were significantly associated with increased risks of NAFLD.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Stephen D. H. Malnick, Pavel Alin, Marina Somin, Manuela G. Neuman
Summary: Both alcohol-induced liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) involve abnormal fat accumulation in the liver, potentially caused by excessive alcohol consumption and the combination of alcohol consumption and medications. The liver pathology is similar in both conditions, progressing from simple steatosis to inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Evaluating the medical history of alcohol consumption, laboratory markers, AST/ALT ratio, and features of the metabolic syndrome can help estimate the contribution of alcohol intake and metabolic syndrome to liver steatosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, General & Internal
Kaitlyn G. Jackson, Grayson W. Way, Huiping Zhou
Summary: Non-alcoholic fatty liver disease (NAFLD) is a rapidly growing disease associated with metabolic syndrome, obesity, diabetes, and insulin resistance. Bile acids and sphingolipids have been identified as potential regulators of hepatic lipid metabolism in NAFLD, and their dysregulation may contribute to the development of the disease.
CHINESE MEDICAL JOURNAL
(2022)